Literature DB >> 9021215

Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.

K E Aldridge1, D Ashcraft, K A Bowman.   

Abstract

A total of 590 strains of clinically important anaerobes were tested to determine their susceptibility to trovafloxacin. Overall, trovafloxacin had a mode MIC of 0.25 micrograms/ml and a MIC at which 90% of the isolates were inhibited of 1 micrograms/ml and had activity comparable to that of metronidazole. Trovafloxacin was 8-, 8-, 16-, 32-, and 64-fold more active than ampicillin-sulbactam, clindamycin, ciprofloxacin, cefoxitin, and cefotetan, respectively. Of the Bacteroides fragilis group, 97% of the isolates were inhibited by trovafloxacin at 21 micrograms/ml, and trovafloxacin was more active than ciprofloxacin, cefoxitin, cefotetan, ampicillin-sulbactam, and clindamycin against Clostridium, Fusobacterium, Porphyromonas, and Prevotella strains.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9021215      PMCID： PMC163737     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

3.  Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.

Authors:  K E Aldridge
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 4.  Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.

Authors:  E J Goldstein
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

5.  The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.

Authors:  J Child; J Andrews; F Boswell; N Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

6.  In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.

Authors:  B B Gooding; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

7.  Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria.

Authors:  M V Borobio; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

8.  Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.

Authors:  R Teng; S C Harris; D E Nix; J J Schentag; G Foulds; T E Liston
Journal:  J Antimicrob Chemother       Date:  1995-08       Impact factor: 5.790

9.  Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.

Authors:  A E Girard; D Girard; T D Gootz; J A Faiella; C R Cimochowski
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191
  10 in total
  11 in total

1.  In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  R Schaumann; G Ackermann; B Pless; M C Claros; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Antibiotic resistance in bacteria isolated from subgingival plaque in a norwegian population with refractory marginal periodontitis.

Authors:  Trude Handal; Dominique A Caugant; Ingar Olsen
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.

Authors:  L E Stearne; I C Gyssens; W H Goessens; J W Mouton; W J Oyen; J W van der Meer; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery.

Authors:  C Martin; A Cotin; A Giraud; M Beccani-Argème; P Alliot; M N Mallet; M Argème
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents.

Authors:  J Mättö; S Asikainen; M L Väisänen; B Von Troil-Lindén; E Könönen; M Saarela; K Salminen; S M Finegold; H Jousimies-Somer
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

7.  [Ampicillin and sulbactam concentrations in the irradiated mandible after oral squamous cell cancer].

Authors:  H Heibel; M Scheer; T Reuther; M Hahn; R Trittler; H Egle; K Kümmerer; A C Kübler
Journal:  Mund Kiefer Gesichtschir       Date:  2005-07

Review 8.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1999       Impact factor: 9.546

9.  Accumulation of norfloxacin by Bacteroides fragilis.

Authors:  V Ricci; L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

10.  Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.

Authors:  D R Snydman; N V Jacobus; L A McDermott; S E Supran
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.